WO2018076782A1 - 右旋奥拉西坦新晶型及其制备方法和用途 - Google Patents
右旋奥拉西坦新晶型及其制备方法和用途 Download PDFInfo
- Publication number
- WO2018076782A1 WO2018076782A1 PCT/CN2017/092219 CN2017092219W WO2018076782A1 WO 2018076782 A1 WO2018076782 A1 WO 2018076782A1 CN 2017092219 W CN2017092219 W CN 2017092219W WO 2018076782 A1 WO2018076782 A1 WO 2018076782A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- crystal form
- form iii
- oxiracetam
- dextrocarbamidine
- crystal
- Prior art date
Links
- IHLAQQPQKRMGSS-SCSAIBSYSA-N NC(CN(C[C@@H](C1)O)C1=O)=O Chemical compound NC(CN(C[C@@H](C1)O)C1=O)=O IHLAQQPQKRMGSS-SCSAIBSYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
Claims (12)
- 一种右旋奥拉西坦晶型III,在衍射角度2θ为17.12±0.2°、18.88±0.2°、19.24±0.2°、21.18±0.2°、24.88±0.2°有衍射峰。
- 如权利要求1所述的右旋奥拉西坦晶型III,其特征在于:所述右旋奥拉西坦晶型III,在衍射角度2θ为18.88±0.2°处的相对峰强度为100%;在衍射角度2θ为21.18±0.2°和24.88±0.2°的相对峰强度大于80%小于100%;在衍射角度2θ为17.12±0.2°、19.24±0.2°的相对峰强度不小于60%。
- 如权利要求1所述的右旋奥拉西坦晶型III,其特征在于:所述右旋奥拉西坦晶型III,在衍射角度2θ为17.12±0.2°、18.88±0.2°、19.24±0.2°、20.66±0.2°、20.84±0.2°、21.18±0.2°、21.82±0.2°、22.94±0.2°、24.88±0.2°、31.52±0.2°有衍射峰。
- 如权利要求1所述的右旋奥拉西坦晶型III,其特征在于:所述右旋奥拉西坦晶型III,在衍射角度2θ为14.44±0.2°、17.12±0.2°、18.88±0.2°、19.24±0.2°、19.78±0.2°、20.66±0.2°、20.84±0.2°、21.18±0.2°、21.82±0.2°、22.94±0.2°、23.24±0.2°、24.88±0.2°、30.46±0.2°、31.40±0.2°、31.52±0.2°有衍射峰。
- 如权利要求1所述的右旋奥拉西坦晶型III,其特征在于:所述晶型具有如图1所示的粉末衍射图谱。
- 如权利要求1-5任一项所述右旋奥拉西坦晶型III的制备方法,采用如下步骤:将右旋奥拉西坦用正丙醇溶解,形成过饱和溶液,然后放置在-12℃~-21℃的低温环境中冷却形成结晶,过滤分离出结晶,干燥,得到右旋奥拉西坦晶型III。
- 如权利要求6所述右旋奥拉西坦晶型III的制备方法,其特征在于,采用如下步骤:在正丙醇中以10mg/mL-55mg/mL的浓度加入右旋奥拉西坦,不断搅拌,35℃~90℃加热溶解,过滤,形成过饱和溶液;然后将过饱和溶液密封放置在-12℃~-21℃的低温环境中冷却形成结晶,过滤分离出结晶,干燥,得到右旋奥拉西坦晶型III。
- 如权利要求6所述右旋奥拉西坦晶型III的制备方法,其特征在于:所述低温环境为-17℃~-19℃。
- 如权利要求1-5任一项所述右旋奥拉西坦晶型III在制备抗癫痫药物中的应用。
- 一种药物组合物,包含如权利要求1-5任一项所述右旋奥拉西坦晶型 III和在药学上可接受的辅料。
- 如权利要求10所述的药物组合物,其特征在于:所述组合物为任何临床上可接受的药物剂型。
- 如权利要求10或11所述的药物组合物,其特征在于:所述组合物为片剂、散剂、颗粒剂、注射剂、胶囊剂、滴丸剂、缓释控释制剂、冻干粉针剂。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/344,337 US10696629B2 (en) | 2016-10-24 | 2017-07-07 | Crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
KR1020197011741A KR20190053253A (ko) | 2016-10-24 | 2017-07-07 | 덱스트랄 옥시라세탐의 새로운 결정형, 이의 제조 방법 및 이의 용도 |
JP2019519377A JP2019531314A (ja) | 2016-10-24 | 2017-07-07 | 右旋性オキシラセタムの新しい結晶型、調製方法、用途 |
EP17865136.0A EP3530272A4 (en) | 2016-10-24 | 2017-07-07 | INNOVATIVE CRYSTALLINE FORM OF DEXTRALOXIRACETAM, PRODUCTION METHOD THEREFOR AND USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610985258.0 | 2016-10-24 | ||
CN201610985258 | 2016-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018076782A1 true WO2018076782A1 (zh) | 2018-05-03 |
Family
ID=62012313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/092219 WO2018076782A1 (zh) | 2016-10-24 | 2017-07-07 | 右旋奥拉西坦新晶型及其制备方法和用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10696629B2 (zh) |
EP (1) | EP3530272A4 (zh) |
JP (1) | JP2019531314A (zh) |
KR (1) | KR20190053253A (zh) |
CN (1) | CN107973737B (zh) |
WO (1) | WO2018076782A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10556863B1 (en) | 2016-10-24 | 2020-02-11 | Chongqing Ruzer Pharmaceutical Company Limited | Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof |
US10696629B2 (en) | 2016-10-24 | 2020-06-30 | Chongqing Runze Pharmaceutical Company Limited | Crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
US10793521B2 (en) | 2016-10-24 | 2020-10-06 | Chongqing Ruzer Pharmaceutical Company Limited | Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof |
US10961192B2 (en) | 2017-01-12 | 2021-03-30 | Chongqing Ruzer Pharmaceutical Company Limited | (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022231257A1 (ko) * | 2021-04-26 | 2022-11-03 | 주식회사 케이에스비튜젠 | 옥시라세탐을 포함하는 근육질환 예방 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102249977A (zh) * | 2011-08-11 | 2011-11-23 | 重庆润泽医疗器械有限公司 | 4-羟基-2-氧代-1-吡咯烷乙酰胺外消旋体晶型ⅰ及其制备方法 |
CN102600130A (zh) * | 2012-03-26 | 2012-07-25 | 北京阜康仁生物制药科技有限公司 | 奥拉西坦及其光学异构体的新临床用途 |
CN102603607A (zh) * | 2011-01-21 | 2012-07-25 | 重庆润泽医疗器械有限公司 | (r)-奥拉西坦的制备方法 |
CN105330582A (zh) * | 2014-08-07 | 2016-02-17 | 重庆东泽医药科技发展有限公司 | (r)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1075280B (it) | 1977-02-11 | 1985-04-22 | Isf Spa | Procedimento per la preparazione di derivati pirrolidinici |
IT1075564B (it) | 1977-02-11 | 1985-04-22 | Isf Spa | Procedimento per la preparazione di derivati pirrolidinici |
KR100679633B1 (ko) | 2004-07-27 | 2007-02-07 | 한국화학연구원 | 광학 활성을 갖는 옥시라세탐의 제조 방법 |
CN102442936A (zh) | 2010-10-09 | 2012-05-09 | 重庆润泽医疗器械有限公司 | 一种(s)-4-羟基-2氧代-1-吡咯烷乙酰胺的纯化方法 |
CN103554000B (zh) * | 2013-11-06 | 2015-03-11 | 重庆润泽医药有限公司 | (s)-奥拉西坦晶型iii及其制备方法和用途 |
CN103553998B (zh) | 2013-11-06 | 2015-11-25 | 温州智创科技有限公司 | (s)-奥拉西坦晶型iii的制备方法 |
CN105820101B (zh) | 2015-01-04 | 2018-12-18 | 哈尔滨三联药业股份有限公司 | 一种旋光纯1-(氨基甲酰基)甲基-4-羟基-2-吡咯烷酮的制备方法 |
US20180147183A1 (en) | 2015-05-18 | 2018-05-31 | Chongqing Runze Pharmaceutical Co., Ltd. | Use of r-oxiracetam in pharmaceutical field |
KR20190053253A (ko) | 2016-10-24 | 2019-05-17 | 충칭 룬즈 파마슈티컬 컴퍼니 리미티드. | 덱스트랄 옥시라세탐의 새로운 결정형, 이의 제조 방법 및 이의 용도 |
CN107973739B (zh) | 2016-10-24 | 2020-03-20 | 重庆润泽医药有限公司 | 右旋奥拉西坦晶型ii及其制备方法和用途 |
EP3530650A4 (en) | 2016-10-24 | 2020-03-25 | Chongqing Runze Pharmaceutical Company Limited | CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF |
CN108299267A (zh) | 2017-01-12 | 2018-07-20 | 重庆润泽医药有限公司 | (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 |
-
2017
- 2017-07-07 KR KR1020197011741A patent/KR20190053253A/ko not_active Application Discontinuation
- 2017-07-07 JP JP2019519377A patent/JP2019531314A/ja active Pending
- 2017-07-07 US US16/344,337 patent/US10696629B2/en active Active
- 2017-07-07 EP EP17865136.0A patent/EP3530272A4/en not_active Withdrawn
- 2017-07-07 WO PCT/CN2017/092219 patent/WO2018076782A1/zh active Application Filing
- 2017-07-07 CN CN201710551259.9A patent/CN107973737B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603607A (zh) * | 2011-01-21 | 2012-07-25 | 重庆润泽医疗器械有限公司 | (r)-奥拉西坦的制备方法 |
CN102249977A (zh) * | 2011-08-11 | 2011-11-23 | 重庆润泽医疗器械有限公司 | 4-羟基-2-氧代-1-吡咯烷乙酰胺外消旋体晶型ⅰ及其制备方法 |
CN102600130A (zh) * | 2012-03-26 | 2012-07-25 | 北京阜康仁生物制药科技有限公司 | 奥拉西坦及其光学异构体的新临床用途 |
CN105330582A (zh) * | 2014-08-07 | 2016-02-17 | 重庆东泽医药科技发展有限公司 | (r)-4-羟基-2-氧代-1-吡咯烷乙酰胺的制备方法 |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 62613-82-5 |
See also references of EP3530272A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10556863B1 (en) | 2016-10-24 | 2020-02-11 | Chongqing Ruzer Pharmaceutical Company Limited | Crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide, preparation method therefor and use thereof |
US10696629B2 (en) | 2016-10-24 | 2020-06-30 | Chongqing Runze Pharmaceutical Company Limited | Crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
US10793521B2 (en) | 2016-10-24 | 2020-10-06 | Chongqing Ruzer Pharmaceutical Company Limited | Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof |
US10961192B2 (en) | 2017-01-12 | 2021-03-30 | Chongqing Ruzer Pharmaceutical Company Limited | (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method therefor, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US20200071270A1 (en) | 2020-03-05 |
US10696629B2 (en) | 2020-06-30 |
EP3530272A1 (en) | 2019-08-28 |
KR20190053253A (ko) | 2019-05-17 |
CN107973737B (zh) | 2020-03-24 |
EP3530272A4 (en) | 2020-03-25 |
JP2019531314A (ja) | 2019-10-31 |
CN107973737A (zh) | 2018-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018076782A1 (zh) | 右旋奥拉西坦新晶型及其制备方法和用途 | |
WO2018076784A1 (zh) | (r)-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型及其制备方法和用途 | |
WO2011143872A9 (zh) | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型及其制备方法和用途 | |
US11053224B2 (en) | Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof | |
WO2018076783A1 (zh) | 右旋奥拉西坦晶型ii及其制备方法和用途 | |
CN110621662B (zh) | 一种盐的结晶性固体形式、制备工艺和使用方法 | |
US10548905B2 (en) | Amorphous onapristone compositions and methods of making the same | |
WO2018130063A1 (zh) | (r)-4-羟基-2-氧-1-吡咯烷乙酰胺的晶型及其制备方法和用途 | |
WO2015067130A1 (zh) | (s)-奥拉西坦晶型iii及其制备方法和用途 | |
JP2018525436A (ja) | オービットアジン−フマル酸塩、水和物、結晶形及びその調製方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17865136 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019519377 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197011741 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017865136 Country of ref document: EP |